{
  "_id": "NCT02120664",
  "title": "Florbetapir Calibration to the Centiloid Scale",
  "text": "Summary: This study is designed to demonstrate the conversion of florbetapir (18F) Positron Emission Tomography (PET) Standard Uptake Value ratio (SUVr) to Centiloid units.\nInclusion criteria: inclusion criteria: \n\n Cognitively Normal Subjects \n\n Males or females ≥ 21 and ≤ 45 years of age \n\n Mini-mental state examination (MMSE) ≥ 29 \n\n Clinically Diagnosed AD Subject \n\n Males or females ≥ 50 years of age \n\n Meet clinical criteria for dementia due to probable AD \n\n MMSE ≥ 16 and ≤ 26 \n\n Possible AD Subject \n\n Males or females ≥ 50 years of age \n\n Meet clinical criteria for dementia due to possible AD \n\n MMSE ≥ 16 and ≤ 26 \n\n MCI Subject \n\n Males or females ≥ 60 years of age with cognitive impairment (not dementia) \n\n MMSE >24 and <29 \n\n At Risk Elderly Subject \n\n Cognitively normal males or females that are known ApoE4 carriers and ≥ 75 years of age \n\n MMSE ≥ 27 \n\n \nExclusion criteria: : \n\n Have had or currently have a diagnosis of neurodegenerative disorders other than AD \n\n Have a current serious or unstable illness that could interfere with completion of the study \n\n Subject has a known brain lesion, pathology or traumatic brain injury \n\n Have received or participated in a trial with investigational medications in the past 30 days \n\n Have had a radiopharmaceutical imaging or treatment procedure within 7 days of study imaging session \n\n Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception",
  "metadata": {
    "brief_title": "Florbetapir Calibration to the Centiloid Scale",
    "phase": "Phase 1",
    "drugs": "['Florbetapir (18F)', '11C-PiB']",
    "drugs_list": [
      "Florbetapir (18F)",
      "11C-PiB"
    ],
    "diseases": "[\"Alzheimer's Disease\"]",
    "diseases_list": [
      "Alzheimer's Disease"
    ],
    "enrollment": "35.0",
    "inclusion_criteria": "inclusion criteria: \n\n Cognitively Normal Subjects \n\n Males or females ≥ 21 and ≤ 45 years of age \n\n Mini-mental state examination (MMSE) ≥ 29 \n\n Clinically Diagnosed AD Subject \n\n Males or females ≥ 50 years of age \n\n Meet clinical criteria for dementia due to probable AD \n\n MMSE ≥ 16 and ≤ 26 \n\n Possible AD Subject \n\n Males or females ≥ 50 years of age \n\n Meet clinical criteria for dementia due to possible AD \n\n MMSE ≥ 16 and ≤ 26 \n\n MCI Subject \n\n Males or females ≥ 60 years of age with cognitive impairment (not dementia) \n\n MMSE >24 and <29 \n\n At Risk Elderly Subject \n\n Cognitively normal males or females that are known ApoE4 carriers and ≥ 75 years of age \n\n MMSE ≥ 27 \n\n ",
    "exclusion_criteria": ": \n\n Have had or currently have a diagnosis of neurodegenerative disorders other than AD \n\n Have a current serious or unstable illness that could interfere with completion of the study \n\n Subject has a known brain lesion, pathology or traumatic brain injury \n\n Have received or participated in a trial with investigational medications in the past 30 days \n\n Have had a radiopharmaceutical imaging or treatment procedure within 7 days of study imaging session \n\n Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception",
    "brief_summary": "This study is designed to demonstrate the conversion of florbetapir (18F) Positron Emission Tomography (PET) Standard Uptake Value ratio (SUVr) to Centiloid units."
  }
}